## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA PHAI Form 4 March 11, 2014		CALS INC	2							
Check this bo if no longer subject to Section 16. Form 4 or Form 5 obligations	<ul> <li>UNITED</li> <li>STATEM</li> <li>Filed put</li> </ul>	<b>MENT O</b>	Wa F CHAN Section	NGES IN SECUI	N OMB Number: Expires: Estimated burden hou response	Number:3235-0287Expires:January 31, 2005Estimated average burden hours per response0.5				
(Print or Type Resp	e. On			•	•	npany Act ny Act of 1	of 1935 or Secti 940	ion		
1. Name and Address of Reporting Person <u>*</u> Mills Roger			2. Issuer Name <b>and</b> Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 11085 TORREYANA ROAD #100			3. Date of Earliest Transaction (Month/Day/Year) 03/07/2014			Director       10% Owner         Officer (give title       Other (specify below)         below)       below)         EVP, DEVELOPMENT AND CMO				
(Street) SAN DIEGO, CA 92121			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>				
(City)	(State)	(Zip)	<b>7</b> 1			a	Person			
1.Title of 2. T	'ransaction Date onth/Day/Year)	2A. Deemo Execution any	ed Date, if	3.	4. Securit mAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Report o	on a separate line	e for each cl	ass of sec	urities bene	Perso inforn requir	ns who res nation cont ed to respo bys a curre	or indirectly. spond to the colle ained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8	]	Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)				
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 27.2	03/07/2014		А		155,000		<u>(1)</u>	03/06/2024	Common Stock	155,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships							
FB	Director	10% Owner	Officer	Other				
Mills Roger 11085 TORREYANA ROAD #100 SAN DIEGO, CA 92121			EVP, DEVELOPMENT AND CMO					
Signatures								
/s/ Glenn F. Baity, Attorney-in-Fact	03/1	1/2014						
**Signature of Reporting Person	E	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares subject to the Stock Option vest and become exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.